Claris Lifesciences Day on Listing: share under pressure

 

Closes 9.7% down – more pressure seen

Claris Lifesciences Limited listed on the BSE today where it had a listing ceremony as well. The listing price or opening price was Rs 224.40. This price was virtually the high for the first two hours of trade as would be visible from the chart appended below. The share after falling to levels of Rs 210 where there was some sort of support available, the share spurted with volume and touched a high of Rs 227.90 just a shade below the issue price and then in a narrow band till just around 3pm. It appears at this time all hell was let loose and the share simply crashed again with huge volume to make the low of the day at Rs 198.10. From here the share did recover some ground to close at Rs 205.85, a loss of Rs 22.15 or 9.71%.

The company had originally issued shares in a price band of Rs 278-293 and had also made an allocation of 18.43 lac shares to anchor investors at the top end of the price band of Rs 293. The issue failed to receive adequate response and the price band was reduced by the maximum 20% to Rs 228-233. The share managed to get subscribe and was priced at the lower end of the price band of Rs 228.

Exchange Open High Low  Close Net Change % gain Wt Avg Volume Delivery Del % age
BSE 224.40 227.90 198.10 205.85 -22.15 -9.71 215.60 15449549 3146850 20.37
Total               15449549 3146850 20.37

The total traded volume was 154.49 lacs which was 1.22 times the IPO size of 126.32 lac shares. The delivery volume was 31.47 lac shares which was 20.37% of the traded volume and 24.91% of the IPO size. The fall in price of over 9.7% compared to the delivery percentage of just about 25% indicated that the share is under pressure and could fall further. The weighted average of the day’s trade was Rs 215.60 which is well above the day’s close of Rs 205.85, indicating sustained selling pressure.

Amongst institutional activity, Copthall Mauritius bought 3.62 lac shares while Deutsche Securities sold 7.68 lac shares and Lakshmi Vilas Bank sold 6.20 lac shares.

Investors would do well to stay away from this share.

Claris Lifesciences: Share lists below issue price

Share trades around Rs 211 – down over 7%

Shares of Claris Lifesciences Limited listed on the BSE where a listing ceremony was held. The listing price was Rs 224.40 and the high was Rs 224.70. The high was made in the first minute of trade and the share price fell thereafter. The share made a low of Rs 200.05 and the share is trading around Rs 210-11. The share has lost over 7% in the first hour of trade.

Exchange Open High Low  Close Net Change % gain Volume Wt Avg
BSE 224.40 224.70 200.05 210.60 -17.40 -7.63 4780690 214.06
Total 4780690

The price band of the issue was Rs 278-293 and due to poor response the price band was reduced by the maximum 20% to Rs 228-233. The share price was then fixed as Rs 228 the lower end of the price band. The traded volume is 47.8 lac shares which is 37.8% of the IPO size of 126.32 lakh shares. The weighted average of the day’s trade is Rs 214 which is higher than the share price currently.

Clearly the price and day’s performance indicate the lack of interest of investors in the issue. It would be interesting to see what levels of trading and where the stock price closes at the end of the day.

Claris Lifesciences IPO to list on Monday 20th December

Claris Lifesciences Limited is to list on Monday the 20th of December. The share would be listed on the BSE and NSE and a listing ceremony would be held at the BSE. The issue had opened on the 24th of November and closed on the 26th of November. The issue was to raise Rs 300 crs in a price band of Rs 278-293. The company had allotted 18.43 lac shares to anchor investors at a price of Rs 293. Unfortunately the issue did not receive adequate response and the price band was reduced by the maximum permissible 20% and the issue dates were extended.

The revised price band was Rs 228-233 and the extended dates were from the 29th of November to the 2nd of December. The issue in its second innings finally got subscribed and received total bids for 161.68 lakh shares and was subscribed 1.5 times. Compared to the basis of allotment one finds that the total demand which was 1,61,68,900 shares reduced by 27,28,494 shares to 1,34,40,406 shares. This effectively means that the issue which was subscribed 1.5 times became 1.24 times due to withdrawals in all segments. QIB’s saw withdrawals of roughly 5.8% of the bids, HNI’s saw a withdrawal of 31.5% of the bids and retail investors saw withdrawals of 24.43%.

The allotment to anchor investors as per SEBI guidelines remains at the allotted price of Rs 293. At this price they are at a loss of Rs 75 per share or 32.89% of the final issue price of Rs 228. It may also be mentioned that since the concept of Anchor Investors was introduced in July 2009, this is the first issue where there was an anchor investor allotment and the price band was revised post the poor performance of the issue. It is also the first time that a company has been forced to reduce the price band by the maximum permissible reduction of 20%. With so many firsts and so many concerns one must be careful about this share and any investment in the same even post listing.

The issue of Claris Lifesciences Limited had issues regarding a company “Core Healthcare Limited”, which was promoted by a relative (father) of the present promoter of the company. It also had issues regarding quality and was issued a warning letter by USFDA as recently as 1st November 2010. Considering the fact that this was a company which is manufacturing injectables, this was a serious concern and accordingly this website had recommended that the issue be not subscribed.

It would be interesting to note how this share fares and what is the performance in the short term and also in the medium term considering all the concerns about the issue.

Subscribe to RSS Feed Follow me on Twitter!